Curis, Inc

Curis, Inc. is a United States-based biopharmaceutical company that employs approximately 51 people. The company is focused on developing innovative cancer therapeutics, with a pipeline that includes emavusertib (CA-4948) for hematologic malignancies, fimepinostat for MYC-altered cancers, and immune checkpoint inhibitors CA-327 and CA-170.